What is the recommended treatment regimen for typhoid fever in adults and children, including first‑line antibiotics, dosing, alternative options if the isolate is fluoroquinolone‑susceptible, and management if there is no clinical improvement within 72 hours?

Typhoid Treatment

For uncomplicated typhoid fever, azithromycin (20 mg/kg/day for 7-14 days, maximum 1g first day then 500mg daily) is the recommended first-line treatment in most endemic regions due to widespread fluoroquinolone resistance, with ceftriaxone (2-4g IV daily) or cefixime (16 mg/kg/day for 14 days) as alternatives. 1, 2

First-Line Treatment Selection

The choice of antibiotic must be guided by local resistance patterns and nalidixic acid susceptibility testing:

When Fluoroquinolone-Susceptible (Nalidixic Acid-Sensitive)

• Ciprofloxacin 500mg twice daily for 7-14 days OR ofloxacin/gatifloxacin at equivalent doses 1
• This scenario is increasingly rare, as 88-94% of isolates in endemic regions are now nalidixic acid-resistant 2

When Nalidixic Acid-Resistant (Most Common Scenario)

• Azithromycin is superior: 1g on day 1, then 500mg daily for 6 more days (total 7 days minimum, up to 14 days) 2, 3
  • Clinical cure rate: 85% vs 71% with cefixime and 62% with ciprofloxacin 2
  • Fever clearance time: 5.8 days vs 7.1 days (cefixime) and 8.2 days (ciprofloxacin) 2
  • Lower relapse rates compared to fluoroquinolones 1

Alternative First-Line Options

• Ceftriaxone 2-4g IV daily for 7-14 days 1, 3
• Cefixime 16 mg/kg/day (400mg twice daily in adults) for 14 days 1, 2

Critical Pitfall: Fluoroquinolone Resistance

Do not use fluoroquinolones empirically in endemic regions. Even when isolates appear "susceptible" by standard disc diffusion (MIC <1 μg/mL), nalidixic acid resistance indicates reduced fluoroquinolone susceptibility with ciprofloxacin MICs of 0.12-1 μg/mL 3, 4. This leads to:

• Clinical failure rates up to 38% 2
• Longer fever duration (10 vs 4 days) 4
• Higher complication rates including perforation 4, 5
• Increased relapse risk 3

Management Without Clinical Improvement at 72 Hours

If fever persists beyond 72 hours on initial therapy:

1. Switch antibiotic class immediately:

   • If on fluoroquinolone → switch to azithromycin or ceftriaxone 3
   • If on azithromycin → switch to ceftriaxone 4g IV daily 3
   • If on cefixime → switch to ceftriaxone IV or add azithromycin 6

2. Obtain blood cultures and antimicrobial susceptibility testing including MIC determination for ciprofloxacin and ceftriaxone 3, 4

3. Evaluate for complications:

   • Intestinal perforation (most common at 2-3 weeks)
   • Hepatic involvement (check transaminases)
   • Neurological complications
   • Myocarditis

Extensively Drug-Resistant (XDR) Typhoid

For isolates resistant to fluoroquinolones, third-generation cephalosporins, AND macrolides:

• Azithromycin PLUS meropenem combination therapy 5, 6
• Meropenem 1-2g IV every 8 hours for 7-10 days
• Consider oral carbapenem (tebipenem) when available 6

Pediatric Dosing

All regimens are weight-based in children:

• Azithromycin: 20 mg/kg/day (max 500mg) for 7-14 days 1, 2
• Ciprofloxacin: 20 mg/kg/day divided twice daily (if susceptible) 2
• Cefixime: 16 mg/kg/day divided twice daily 2
• Ceftriaxone: 75-100 mg/kg/day (max 4g) 1

The historical concern about fluoroquinolone cartilage toxicity in children has not materialized in clinical practice 7, but resistance patterns make this concern largely academic.

Duration of Treatment

• Azithromycin: 7 days minimum, extend to 14 days if slow response 2, 6
• Fluoroquinolones: 7-14 days (when susceptible) 1, 8
• Ceftriaxone/Cefixime: 10-14 days 1, 2

Shorter courses (3-5 days) of fluoroquinolones were effective historically 7 but are no longer reliable given current resistance patterns.

Key Evidence Considerations

The WHO 2012 guidelines 1 recommending fluoroquinolones first-line are outdated given resistance evolution. The 2024 WHO essential medicines guidance 1 and recent RCT data 2 support azithromycin as the preferred empiric choice in endemic regions. Ceftriaxone remains highly effective but requires parenteral administration, making it less practical for outpatient management 1, 6.